Retour sur lavenir.net
   CMB.TECH 12.680 € (+0,32 %)     RECTICEL 10.460 € (+0,77 %)     AGEAS 67.800 € (+0,74 %)     ARGENX SE 687.600 € (-0,12 %)     AB INBEV 67.970 € (-3,40 %)     UCB 235.600 € (-0,17 %)     TUBIZE-FIN 201.000 € (-0,69 %)     WDP 22.500 € (-0,53 %)     MELEXIS 76.800 € (+0,13 %)     ELIA GROUP 137.600 € (-1,22 %)     SOLVAY 26.140 € (-9,42 %)     BEKAERT 44.200 € (+0,45 %)     AZELIS GROUP 10.450 € (-3,24 %)     DEME GROUP 204.500 € (+0,49 %)     SYENSQO 57.850 € (-1,62 %)     BPOST 1.640 € (-3,53 %)     XIOR 27.900 € (+0,72 %)     RETAIL ESTATES 67.600 € (-0,73 %)     BARCO 9.075 € (-1,25 %)     KBC ANCORA 80.400 € (+0,50 %)     KBC 116.750 € (+0,60 %)     PROXIMUS 6.605 € (0,00 %)     TITAN S.A. 51.650 € (+4,55 %)     NYXOAH 2.750 € (+1,29 %)     ACKERMANS V.HAAREN 296.000 € (-0,13 %)     UMICORE 21.420 € (+3,08 %)     GIMV 48.900 € (+0,62 %)     ONTEX GROUP 2.890 € (-0,17 %)     EKOPAK 4.500 € (+1,01 %)     COLRUYT 32.400 € (-2,00 %)     TESSENDERLO 21.700 € (0,00 %)     ORANGE BELGIUM 21.200 € (0,00 %)     VIOHALCO 17.600 € (+1,38 %)     CIE BOIS SAUVAGE 329.000 € (+0,92 %)     OXURION 0.004 € (0,00 %)     SHURGARD 26.250 € (+0,57 %)     EVS BROADC.EQUIPM. 37.550 € (+0,40 %)     LOTUS BAKERIES 10 860.000 € (+1,12 %)     FLUXYS BELGIUM D 22.200 € (-1,77 %)     MONTEA 69.500 € (-1,84 %)     VASTNED 28.900 € (+1,05 %)     D'IETEREN GROUP 182.300 € (-0,92 %)     AEDIFICA 72.450 € (-0,41 %)     COFINIMMO 84.900 € (-0,59 %)     BIOTALYS 2.915 € (-2,18 %)     TINC 12.100 € (-0,66 %)     SOFINA 221.000 € (-1,52 %)     FAGRON 24.700 € (-0,60 %)     DECEUNINCK 2.070 € (+0,49 %)     IBA 14.820 € (+0,27 %)     KINEPOLIS GROUP 30.400 € (+0,16 %)     CFE 11.700 € (+0,43 %)     ONWARD MEDICAL 2.720 € (+0,74 %)     CELYAD ONCOLOGY 0.310 € (-2,52 %)     GBL 81.950 € (-0,30 %)     ECONOCOM GROUP 1.400 € (0,00 %)     BREDERODE 102.800 € (-0,19 %)     INCLUSIO SA/NV 17.650 € (-0,84 %)     SIPEF 100.000 € (-1,38 %)     HOME INVEST BE. 19.200 € (-0,93 %)  
   CVC CAPITAL 13.510 € (-0,22 %)     EMEIS 15.410 € (+0,78 %)     FERMENTALG 0.572 € (-4,03 %)     FDJ UNITED 22.870 € (-0,48 %)     VIRIDIEN 115.500 € (-3,27 %)     AYVENS 11.320 € (-0,70 %)     PULLUP ENTERTAIN 8.770 € (-0,90 %)     OPMOBILITY 15.680 € (+1,23 %)     METAVISIO 0.001 € (+9,09 %)     CEGEDIM 10.960 € (+1,29 %)     EXOSENS 62.900 € (-2,25 %)     FERROVIAL 60.660 € (-0,36 %)     TITAN 2.700 € (-14,01 %)     PLANISWARE 17.950 € (+0,50 %)     CARREFOUR 17.145 € (+0,03 %)     THALES 237.000 € (-1,66 %)     LVMH 484.050 € (+2,12 %)     EUROFINS SCIENT. 60.260 € (+0,43 %)     VEOLIA ENVIRON. 36.460 € (+0,72 %)     GTT 209.600 € (-0,47 %)     DASSAULT AVIATION 305.000 € (-0,91 %)     GALP ENERGIA-NOM 19.010 € (-1,48 %)     AIR LIQUIDE 177.460 € (-1,56 %)     STMICROELECTRONICS 48.715 € (+0,44 %)     ELIS 28.060 € (+1,67 %)     AIRBUS 185.960 € (-1,35 %)     ENGIE 27.280 € (-1,05 %)     SCHNEIDER ELECTRIC 283.850 € (+0,41 %)     EXAIL TECHNOLOGIES 115.000 € (-5,27 %)     ALTEN 62.400 € (+0,89 %)     SAFRAN 299.400 € (+0,91 %)     BONDUELLE 8.160 € (-4,23 %)     PUBLICIS GROUPE SA 81.800 € (+0,15 %)     BOUYGUES 51.320 € (-3,17 %)     74SOFTWARE 37.200 € (+0,54 %)     SOCIETE GENERALE 70.830 € (+1,19 %)     L'OREAL 370.950 € (-0,66 %)     UBISOFT ENTERTAIN 4.855 € (-1,40 %)     TOTALENERGIES 75.260 € (-1,94 %)     ABIVAX 106.800 € (-3,09 %)     PROSUS 42.385 € (+1,21 %)     AXA 41.620 € (-0,43 %)     ASML HOLDING 1 306.000 € (+0,08 %)     SANOFI 73.930 € (-0,95 %)     SOITEC 150.450 € (+2,45 %)     WOLTERS KLUWER 61.540 € (-2,96 %)     COFACE 16.260 € (+0,56 %)     ADOCIA 5.075 € (+5,64 %)     ADYEN 964.300 € (+0,70 %)     RELX 28.760 € (-5,27 %)     UNILEVER 50.510 € (-0,30 %)     AEGON 7.168 € (+0,06 %)     PHARMING GROUP 1.099 € (-21,22 %)     SHELL PLC 36.385 € (-2,06 %)     ABN AMRO BANK N.V. 30.560 € (+1,13 %)     BUREAU VERITAS 26.860 € (+0,22 %)     SMCP 5.255 € (+0,77 %)     BNP PARIBAS ACT.A 93.720 € (+0,33 %)     CSG 16.368 € (-4,03 %)     ESSILORLUXOTTICA 177.600 € (+0,51 %)  
News Réglementées
16/04/2026 20:35

EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year

EQS-Ad-hoc: Drägerwerk AG & Co. KGaA / Key word(s): Results / Quarter/Forecast / Full year
Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year

16-Apr-2026 / 20:35 CET/CEST
Correction of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year

Lübeck, April 16, 2026 – Following a decline in the same period of the prior year, Dräger’s net sales rose by 6.9 percent (net of currency effects; nominal: 3.5 percent) in the first quarter of 2026, based on preliminary calculations. At around EUR 766 million, they were around EUR 26 million above the prior-year figure (3 months 2025: EUR 730.3 million). Both divisions were able to grow again: the medical division posted an increase of 5.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 418 million (3 months 2025: EUR 413.1 million), while the safety division recorded an increase of 8.8 percent (net of currency effects; nominal: 6.6 percent) to around EUR 338 million (3 months 2025: EUR 317.2 million).

Earnings before interest and taxes (EBIT) increased significantly to around EUR 18 million (3 months 2025: EUR 0.4 million). The EBIT margin rose to around 2.4 percent (3 months 2025: 0.1 percent). The main reason for this was the positive net sales development as well as the improvement in the gross margin to around 46.3 percent (3 months 2025: 45.8 percent). In addition, functional expenses fell by around EUR 2.7 million to around EUR 331 million (3 months 2025: EUR 333.7 million), partly as a result of a one-off payment for employees in Germany due to collective wage agreements in the prior year.

Order intake increased by 3.4 percent (net of currency effects; nominal: 0.5 percent) to around EUR 865 million (3 months 2025: EUR 860.8 million). Both divisions were able to contribute to growth: In the medical division, order intake rose by 5.2 percent (net of currency effects; nominal: 1.3 percent) to around EUR 480 million (3 months 2025: EUR 473.7 million), while in the safety division it increased by 1.2 percent (net of currency effects; nominal: -0.6 percent) to around EUR 385 million (3 months 2025: EUR 387.1 million).

Forecast for 2026
For the current fiscal year, Dräger continues to expect an increase in net sales of 1.0 to 5.0 percent (2.0 to 6.0 percent net of currency effects) and an EBIT margin of 5.0 to 7.5 percent.

The full results for the first three months of the fiscal year will be published on April 30, 2026.

 

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

 

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

 

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.



End of Inside Information

Changed circumstances / true information:

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year

Lübeck, April 16, 2026 – Following a decline in the same period of the prior year, Dräger’s net sales rose by 6.9 percent (net of currency effects; nominal: 3.5 percent) in the first quarter of 2026, based on preliminary calculations. At around EUR 756 million, they were around EUR 26 million above the prior-year figure (3 months 2025: EUR 730.3 million). Both divisions were able to grow again: the medical division posted an increase of 5.4 percent (net of currency effects; nominal: 1.1 percent) to around EUR 418 million (3 months 2025: EUR 413.1 million), while the safety division recorded an increase of 8.8 percent (net of currency effects; nominal: 6.6 percent) to around EUR 338 million (3 months 2025: EUR 317.2 million).

Earnings before interest and taxes (EBIT) increased significantly to around EUR 18 million (3 months 2025: EUR 0.4 million). The EBIT margin rose to around 2.4 percent (3 months 2025: 0.1 percent). The main reason for this was the positive net sales development as well as the improvement in the gross margin to around 46.3 percent (3 months 2025: 45.8 percent). In addition, functional expenses fell by around EUR 2.7 million to around EUR 331 million (3 months 2025: EUR 333.7 million), partly as a result of a one-off payment for employees in Germany due to collective wage agreements in the prior year.

Order intake increased by 3.4 percent (net of currency effects; nominal: 0.5 percent) to around EUR 865 million (3 months 2025: EUR 860.8 million). Both divisions were able to contribute to growth: In the medical division, order intake rose by 5.2 percent (net of currency effects; nominal: 1.3 percent) to around EUR 480 million (3 months 2025: EUR 473.7 million), while in the safety division it increased by 1.2 percent (net of currency effects; nominal: -0.6 percent) to around EUR 385 million (3 months 2025: EUR 387.1 million).

Forecast for 2026
For the current fiscal year, Dräger continues to expect an increase in net sales of 1.0 to 5.0 percent (2.0 to 6.0 percent net of currency effects) and an EBIT margin of 5.0 to 7.5 percent.

The full results for the first three months of the fiscal year will be published on April 30, 2026.

 

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

 

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

 

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.


16-Apr-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language:English
Company:Drägerwerk AG & Co. KGaA
Moislinger Allee 53-55
23558 Lübeck
Germany
Phone:+49 (0)451 882-0
Fax:+49 (0)451 882-2080
E-mail:info@draeger.com
Internet:www.draeger.com
ISIN:DE0005550602, DE0005550636 (Vorzugsaktien)
WKN:555060, 555063 (Vorzugsaktien)
Indices:SDAX, TecDax
Listed:Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart, Tradegate BSX
EQS News ID:2310104

 
End of AnnouncementEQS News Service

2310104  16-Apr-2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière